Valneva Se Stock News

Valneva SE (NASDAQ: VALN) proposed a remediation plan after receiving the European Commission's notice of intent to terminate the advance purchase agreement for its inactivated COVID-19 vaccine can

U.S.-listed shares of Valneva SE VALN, -3.09% VLA, +10.48% jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its C

The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union. Ea

(Reuters) -Valneva lost nearly a fifth of its value on Monday after the French drugmaker said its COVID-19 vaccine agreement with the European Commission was likely to be scrapped and it might have to

Valneva SE (NASDAQ:VALN ) Q1 2022 Earnings Conference Call May 5, 2022 10:00 AM ET Company Participants Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer Franck Grimau

The Scottish unit of French vaccine maker Valneva has received a grant of up to 20 million pounds ($27 million) to partly fund the research and development (R&D) of manufacturing its COVID-19 vaccine VLA2001, the company said on Monday. Valneva will receive the funds from Scotland''s national economic development agency Scottish Enterprise, which it has been in talks with since December. The funding will come in two tranches. The first grant of up to 12.5 million pounds will support the company''s efforts on the VLA2001, its inactivated, whole virus COVID-19 vaccine candidate. The second round of up to 7.5 million pounds will be used for Valneva''s other vaccines. Apart from the highly awaited COVID-19 vaccine, Valneva is developing VLA1553, a mosquito-born viral infection chikungunya vaccine, which it intends to produce in the Scottish town of Livingston, near Edinburgh. It has recently reported positive phase 3 data for both VLA2001 and VLA1553. 4.7m doses of Pfizer vaccine arrive "Valneva is a valued contributor to our life sciences sector and the Livingston facility

Talks continue with the Scottish Government over the potential purchase of the Livingston-made Covid-19 vaccine

Read More The post £20m support for vaccine firm Valnevas Scots plant appeared first on Daily Business .

(Reuters) The Scottish unit of French vaccine maker Valneva has received a grant of up to 20 million pounds ($27 million) to partly fund the research and development of manufacturing its COVID-19 vaccine VLA2001, the company said on Monday.

Saint Herblain ( France), February 21 , 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise.

Valneva and Pfizer plan a three-dose primary series for a phase 3 trial of its Lyme disease vaccine candidate, VLA15

Valneva SE (NASDAQ: VALN ) and Pfizer Inc (NYSE: PFE ) have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. These data are consistent with the strong immunogenicity profile observed for this age group in Full story available on Benzinga.com

(Reuters) French vaccine developer Valneva targets increasing its revenues year-on-year by up to 70% thanks to a boost from its COVID-19 vaccine candidate, it said on Thursday.

Valneva SE (NASDAQ: VALN ) has initiated a Phase 3 trial in adolescents for its single-shot chikungunya vaccine candidate, VLA1553. The collaboration falls within the framework of the agreement signed between Coalition for Epidemic Preparedness Innovations and Valneva in July 2019, which provides funding of up to $23.4 million with support from the European Union''s Horizon 2020 program. It is also expected to support the vaccine''s licensure Full story available on Benzinga.com

Valneva (VALN) said that a phase 3 trial of its single-shot chikungunya vaccine candidate VLA1553 in adolescents has begun in Brazil